Relative Bioequivalence of Loxoprofen Sodium in Healthy Volunteers

Yao CHEN,Zhi-rong TAN,Gan ZHOU,Yi-cheng WANG,Zhi LI,Hong-hao ZHOU
DOI: https://doi.org/10.3969/j.issn.1672-2981.2011.10.007
2011-01-01
Abstract:Objective To study the relative bioequivalence of loxoprofen sodium made by Guangdong Xianqiang Pharmaceutical Co.,Ltd.Methods A single oral dose of 60 mg domestic loxoprofen sodium,and its contrast drug made by Shanghai Sankyo Pharmaceuticals Co.,Ltd.were given to 18 healthy volunteers in an open randomized two way crossover design.The plasma concentrations were determined by HPLC method.Results The main pharmacokinetic parameters of loxoprofen sodium were as follows :Cmax was(5 221.3±1 726.1) and(5 309.0±1 946.1) ng·mL-1;tmax was(0.61±0.26) and(0.69±0.30)h;AUC0~6 was(9 507.2±4 062.0) and(9 380.5±3 765.3) ng·h·mL-1;AUC0~∞ was(10 580.8±4 385.6) and(10 552.4±3 852.8) ng·h·mL-1 for the reference drug and the test drug,respectively.The relative bioavailability of loxoprofen sodium was 106.7%(94.8%-120%).Conclusion The reference preparation and the test preparation are bioequivalent.
What problem does this paper attempt to address?